66 / 82
CARDIOVASCULAR JOURNAL OF AFRICA • Volume 29, No 1, January/February 2018
64
AFRICA
170. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol
CR/XL Randomised Intervention Trial in Congestive Heart Failure
(MERIT-HF).
Lancet
1999;
353
(9169): 2001–2007.
171. Poole-Wilson PA, Swedberg K, Cleland JG,
et al
. Comparison of carve-
dilol and metoprolol on clinical outcomes in patients with chronic heart
failure in the Carvedilol Or Metoprolol European Trial (COMET):
randomised controlled trial.
Lancet
2003;
362
(9377): 7–13.
172. Naccarelli GV, Lukas MA. Carvedilol’s antiarrhythmic properties:
therapeutic implications in patients with left ventricular dysfunction.
Clin Cardiol
2005;
28
(4): 165–173.
173. Bristow MR. beta-adrenergic receptor blockade in chronic heart failure.
Circulation
2000;
101
(5): 558–569.
174. Nagatsu M, Spinale FG, Koide M,
et al.
Bradycardia and the role
of beta-blockade in the amelioration of left ventricular dysfunction.
Circulation
2000;
101
(6): 653–659.
175. Communal C, Singh K, Sawyer DB, Colucci WS. Opposing effects of
beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis:
role of a pertussis toxin-sensitive G protein.
Circulation
1999;
100
(22):
2210–2212.
176. Mason RP, Giles TD, Sowers JR. Evolving mechanisms of action of
beta blockers: focus on nebivolol.
J Cardiovasc Pharmacol
2009;
54
(2):
123–128.
177. Saini-Chohan HK, Hatch GM. Biological actions and metabolism of
currently used pharmacological agents for the treatment of congestive
heart failure.
Curr Drug Metab
2009;
10
(3): 206–219.
178. Wu TC, Chen YH, Leu HB,
et al
. Carvedilol, a pharmacological anti-
oxidant, inhibits neointimal matrix metalloproteinase-2 and -9 in experi-
mental atherosclerosis.
Free Radic Biol Med
2007;
43
(11): 1508–1522.
179. Lohse MJ, Engelhardt S, Eschenhagen T. What is the role of beta-
adrenergic signaling in heart failure?
Circ Res
2003;
93
(10): 896–906.
180. Trappanese DM, Liu Y, McCormick RC,
et al.
Chronic beta1-adrener-
gic blockade enhances myocardial beta3-adrenergic coupling with nitric
oxide-cGMP signaling in a canine model of chronic volume overload:
new insight into mechanisms of cardiac benefit with selective beta1-
blocker therapy.
Basic Res Cardiol
2015;
110
(1): 456.
181. Starling MR. Effects of valve surgery on left ventricular contractile
function in patients with long-term mitral regurgitation.
Circulation
1995;
92
(4): 811–818.
182. Witkowski TG, Thomas JD, Delgado V,
et al
. Changes in left ventricular
function after mitral valve repair for severe organic mitral regurgitation.
Ann Thorac Surg
2012;
93
(3): 754–760.
183. Kainuma S, Taniguchi K, Toda K,
et al.
B-type natriuretic peptide
response and reverse left ventricular remodeling after surgical correction
of functional mitral regurgitation in patients with advanced cardiomyo-
pathy.
J Cardiol
2015;
66
(4): 279–285.
184. Bonow RO, Carabello BA, Chatterjee K,
et al
. 2008 focused update
incorporated into the ACC/AHA 2006 guidelines for the management
of patients with valvular heart disease: a report of the American College
of Cardiology/American Heart Association Task Force on Practice
Guidelines (Writing Committee to revise the 1998 guidelines for the
management of patients with valvular heart disease). Endorsed by the
Society of Cardiovascular Anesthesiologists, Society for Cardiovascular
Angiography and Interventions, and Society of Thoracic Surgeons.
J
Am Coll Cardiol
2008;
52
(13): e1–142.
185. Hetzer R, Dandel M. Early detection of left ventricular dysfunction in
patients with mitral regurgitation due to flail leaflet is still a challenge.
Eur Heart J
2011;
32
(6): 665–667.
186. Carabello BA. Beta-blockade for mitral regurgitation: could the
management of valvular heart disease actually be moving into the 21st
century?
J Am Coll Cardiol
2012;
60
(9): 839–840.
187. Samad Z, Kaul P, Shaw LK, et al. Impact of early surgery on survival
of patients with severe mitral regurgitation.
Heart
2011;
97
(3): 221–224.
188. Kang DH, Park SJ, Sun BJ,
et al
. Early surgery versus conventional
treatment for asymptomatic severe mitral regurgitation: a propensity
analysis.
J Am Coll Cardiol
2014;
63
(22): 2398–2407.
189. Yazdchi F, Koch CG, Mihaljevic T,
et al
. Increasing disadvantage of
‘watchful waiting’ for repairing degenerative mitral valve disease.
Ann
Thorac Surg
2015;
99
(6): 1992–2000.
190. Barbieri A, Bursi F, Grigioni F,
et al
. Prognostic and therapeutic impli-
cations of pulmonary hypertension complicating degenerative mitral
regurgitation due to flail leaflet: a multicenter long-term international
study.
Eur Heart J
2011;
32
(6): 751–759.
191. Rosenhek R, Rader F, Klaar U,
et al.
Outcome of watchful waiting in
asymptomatic severe mitral regurgitation.
Circulation
2006;
113
(18):
2238–2244.
192. Eskesen K, Olsen NT, Dimaano VL, Fritz-Hansen T, Sogaard P,
Abraham TP. Effects of early and late-onset treatment with carvedilol in
an experimental model of aortic regurgitation.
Springerplus
2015;
4
: 52.
193. Carabello BA. The current therapy for mitral regurgitation.
J Am Coll
Cardiol
2008;
52
(5): 319–326.
194. Wisenbaugh T. Vasoactive medications in the treatment of severe mitral
regurgitation.
Coron Artery Dis
2000;
11
(1): 19–22.
195. Wisenbaugh T, Sinovich V, Dullabh A, Sareli P. Six month pilot study
of captopril for mildly symptomatic, severe isolated mitral and isolated
aortic regurgitation.
J Heart Valve Dis
1994;
3
(2): 197–204.
196. Stewart RA, Raffel OC, Kerr AJ,
et al
. Pilot study to assess the influ-
ence of beta-blockade on mitral regurgitant volume and left ventricular
work in degenerative mitral valve disease.
Circulation
2008;
118
(10):
1041–1046.
197. Ennis DB, Rudd-Barnard GR, Li B,
et al
. Changes in mitral annular
geometry and dynamics with ss-blockade in patients with degenerative
mitral valve disease.
Circ Cardiovasc Imaging
2010;
3
(6): 687–693.
198. Varadarajan P, Joshi N, Appel D, Duvvuri L, Pai RG. Effect of Beta-
blocker therapy on survival in patients with severe mitral regurgitation
and normal left ventricular ejection fraction.
Am J Cardiol
2008;
102
(5):
611–615.
199. Ahmed MI, Aban I, Lloyd SG,
et al.
A Randomized controlled phase
IIb trial of beta1-receptor blockade for chronic degenerative mitral
regurgitation.
J Am Coll Cardiol
2012;
60
(9): 833–838.
200. Pat B, Killingsworth C, Denney T,
et al
. Dissociation between cardiomy-
ocyte function and remodeling with beta-adrenergic receptor blockade
in isolated canine mitral regurgitation.
Am J Physiol Heart Circ Physiol
2008;
295
(6): H2321–2327.
201. Pu M, Gao Z, Pu DK, Davidson WR Jr. Effects of early, late, and long-
term nonselective beta-blockade on left ventricular remodeling, func-
tion, and survival in chronic organic mitral regurgitation.
Circ Heart
Fail
2013;
6
(4): 756–762.
202. Capomolla S, Febo O, Gnemmi M,
et al
. Beta-blockade therapy
in chronic heart failure: diastolic function and mitral regurgitation
improvement by carvedilol.
Am Heart J
2000;
139
(4): 596–608.